Cardiovascular effects of methadone and concomitant use of diazepam during methadone maintenance treatment induction: low concentration risk

References

• Veilleux JC, Colvin PJ, Anderson J, et al. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction. Clin Psychol Rev. 2010;30:155–166.
   PubMed Web of Science ®Google Scholar
• Novick DM, Salsitz EA, Joseph H, et al. Methadone medical maintenance: an early 21st-century perspective. J Addict Dis. 2015;34:226−37.
   PubMed Web of Science ®Google Scholar
• Arora A, Williams K. Problem based review: the patient taking methadone. Acute Med. 2013;12:51−4.
   PubMedGoogle Scholar
• Narang A, Ozcan C. Severe Torsades de Pointes with acquired QT prolongation. Eur Heart J Acute Cardiovasc Care. 2016. DOI:10.1177/2048872616649473
   PubMedGoogle Scholar
• Lin C, Somberg T, Molnar J, et al. The effects of chiral isolates of methadone on the cardiac potassium channel IKr. Cardiology. 2009;113:59–65.
   PubMed Web of Science ®Google Scholar
• Garsojn A. How to measure the QT interval – what is normal? Am J Cardiol. 1993;72:14B−16B.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991;84:1136–1144.
   PubMed Web of Science ®Google Scholar
• Savić N, Gojković-Bukarica L. Long QT syndrome: genetic implications and drug influence. Vojnosanitetski Pregled. 2008;65:308–312.
   PubMed Web of Science ®Google Scholar
• Uvelin A, Pejaković J, Mijatović V. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist. J Anesth. 2017;31(3):413–423.
   PubMed Web of Science ®Google Scholar
• Csajka C, Crettol S, Guidi M, et al. Population genetic-based pharmacokinetic modeling of methadone and its relationship with the QTc interval in opioid-dependent patients. Clin Pharmacokinet. 2016;55(12):1521–1533.
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Moody DE, Knight S, et al. A possible mechanistic link between the CYP2C19 genotype, the methadone metabolite ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP), and methadone-induced corrected QT interval prolongation in a pilot study. Mol Diagn Ther. 2015;19:131–138.
   PubMed Web of Science ®Google Scholar
• Hajj A, Ksouda K, Peoc’h K, et al. KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug and Alcohol Dependance. 2014;141:34–38.
   PubMed Web of Science ®Google Scholar
• Mijatović V, Samojlik I, Petković S, et al. Consequences of cardiac toxicity in patients on low methadone doses during methadone maintenance treatment. Heroin Addict Relat Clin Probl. 2015;17(1):73–78.
   Web of Science ®Google Scholar
• Fields MD, Abate MA, Hu L, et al. Parent and metabolite opioid drug concentrations in unintentional deaths involving opioid and benzodiazepine combinations. J Forensic Sci. 2015;60:950−6.
   PubMed Web of Science ®Google Scholar
• Petrushevska T, Jakovski Z, Poposka V, et al. Drug-related deaths between 2002 and 2013 with accent to methadone and benzodiazepines. J Forensic Leg Med. 2015;31:12−8.
   PubMed Web of Science ®Google Scholar
• Simonsen KW, Edvardsen HM, Thelander G, et al. Fatal poisoning in drug addicts in the Nordic countries in 2012. Forensic Sci Int. 2015;248:172−80.
   PubMed Web of Science ®Google Scholar
• Lee SC, Klein-Schwartz W, Doyon S, et al. Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. Drug and Alcohol Dependance. 2014;138:118−23.
   PubMed Web of Science ®Google Scholar
• Schuster JM, Loveland D, Parthasarathy M, et al. Reducing problematic benzodiazepine use among individuals enrolled in methadone treatment programs. J Addict Med. 2016;10:202–207.
   PubMed Web of Science ®Google Scholar
• Kao D, Bartelson BB, Khatri V, et al. Trends in reporting methadone-associated cardiac arrhythmia, 1997−2011. Ann Intern Med. 2013;158:735−40.
   PubMed Web of Science ®Google Scholar
• Peles E, Linzy S, Kreek MJ, et al. Prospective study of QTc changes among former opiate addicts since admission to methadone maintenance treatment: benzodiazepine risk. J Addict Med. 2013;7:428−34.
   PubMed Web of Science ®Google Scholar
• Mijatović V, Samojlik I, Ajduković N, et al. Methadone-related deaths - epidemiological, pathohistological, and toxicological traits in 10-year retrospective study in Vojvodina, Serbia. J Forensic Sci. 2014;59:1280−5.
   PubMed Web of Science ®Google Scholar
• Kuryshev YA, Bruening-Wright A, Brown AM, et al. Increased cardiac risk in concomitant methadone and diazepam treatment: pharmacodynamic interactions in cardiac ion channels. J Cardiovasc Pharmacol. 2010;56:420−30.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. International statistical classification of diseases and related health problems. 10th Revision (ICD-10). Geneva: WHO; 2010.
   Google Scholar
• Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501−4.
   PubMed Web of Science ®Google Scholar
• Katchman AN, McGroary KA, Kilborn MJ, et al. Influence of opioid agonists on cardiac human ether-a-go-gorelated gene K currents. J Pharmacol Exp Ther. 2002;303:688−94.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Public health advisory: methadone use for pain control may result in death and life-threatening changes in breathing and heart beat. [cited June 26, 2017]. https://wayback.archive-it.org/7993/20170406045016/https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124346.htm.
   Google Scholar
• Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med. 2009;150:387–395.
   PubMed Web of Science ®Google Scholar
• Martell BA, Arnsten JH, Krantz MJ, et al. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005;95:915−8.
   PubMed Web of Science ®Google Scholar
• Florian J, Garnett CE, Nallani SC, et al. A modelling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients. Clin Pharmacol Ther. 2012;91:666−72.
   PubMed Web of Science ®Google Scholar
• Chang KC, Huang CL, Liang HY, et al. Gender-specific differences in susceptibility to low-dose methadone-associated QTc prolongation in patients with heroin dependence. J Cardiovasc Electrophysiol. 2012;23:527–533.
   PubMed Web of Science ®Google Scholar
• Reddy S, Hui D, El Osta B, et al. The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study. J Palliat Med. 2010;13:33−8.
   PubMed Web of Science ®Google Scholar
• Anchersen K, Clausen T, Gossop M, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104:993−9.
   PubMed Web of Science ®Google Scholar
• Fonseca F, Marti-Almor J, Pastor A, et al. Prevalence of long QTc interval in methadone maintenance patients. Drug and Alcohol Dependance. 2009;99:327−32.
   PubMed Web of Science ®Google Scholar
• Ehret GB, Voide C, Gex-Fabry M, et al. Drug induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med. 2006;166:1280−7.
   PubMed Web of Science ®Google Scholar
• Cruciani RA, Sekine R, Homel P, et al. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage. 2005;29:385−91.
   PubMed Web of Science ®Google Scholar
• Stallvik M, Nordstrand B, Kristensen O, et al. Corrected QT interval during treatment with methadone and buprenorphine − relation to doses and serum concentrations. Drug and Alcohol Dependance. 2013;129:88−93.
   PubMed Web of Science ®Google Scholar
• Eap CB, Crettol S, Rougier JS, et al. Stereoselective block of hERG Channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81:719–728.
   PubMed Web of Science ®Google Scholar
• Peles E, Bodner G, Kreek MJ, et al. Corrected-QT intervals as related to methadone dose and serum level in methadone maintenance treatment (MMT) patients – a cross sectional study. Addiction. 2007;102:289−300.
   PubMed Web of Science ®Google Scholar
• Skjervold B, Bathen J, Spigset O. Methadone and QT interval: relations to the serum concentrations of methadone and its enantiomers (R)-methadone and (S)-methadone. J Clin Psychopharmacol. 2006;26:687−9.
   PubMed Web of Science ®Google Scholar
• Darke S, Kaye S, Duflou J. Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. Addiction. 2006;101:1771−7.
   PubMed Web of Science ®Google Scholar
• Darke S, Kaye S, Duflou J. Systemic disease among cases of fatal opioid toxicity. Addiction. 2006;101:1299−1305.
   PubMed Web of Science ®Google Scholar
• Butler B, Rubin G, Lawrance A, et al. Estimating the risk of fatal arrhythmia in patients in methadone maintenance treatment for heroin addiction. Drug Alcohol Rev. 2011;30:173−180.
   PubMed Web of Science ®Google Scholar
• Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France. Fundam Clin Pharmacol. 2011;25:503−10.
   PubMed Web of Science ®Google Scholar